Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: INSP stock price vs AMGN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AMGN's multiple
Needs AMGN P/E.
Implied fair value · at INSP's multiple
Needs INSP P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: INSP FY 2025 (ended Dec 31, 2025) · AMGN FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
Inspire Medical Systems, Inc. · implied price per share
Bear
$14.19
Base
$16.69
Bull
$19.20
Amgen Inc. · implied price per share
Bear
$167.69
Base
$197.28
Bull
$226.87
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.04x
6.84x
Net debt / EBITDA
Leverage against operating earnings
-4.05x
0.87x
Cash and equivalents
Liquid reserves on the balance sheet
$308.27M
$47.01B
Total debt
Interest-bearing obligations outstanding
$33.69M
$59.20B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
BOSTON SCIENTIFIC CORP
INSP vs BSX
Medtronic plc
INSP vs MDT
ABBOTT LABORATORIES
INSP vs ABT
JOHNSON & JOHNSON
INSP vs JNJ
LivaNova PLC
INSP vs LIVN
REGENERON PHARMACEUTICALS, INC.
INSP vs REGN
BIOGEN INC.
INSP vs BIIB
VERTEX PHARMACEUTICALS INC / MA
INSP vs VRTX
Gilead Sciences, Inc.
INSP vs GILD
Moderna, Inc.
INSP vs MRNA
Eli Lilly and Company
INSP vs LLY
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe INSP can sustain 13.6% revenue growth while expanding operating margin from 5.6% toward AMGN-like levels, then the stock looks attractive to own because it is priced at 9.6x earnings and 1.5x sales versus AMGN’s richer multiples.
INSP trades at a steep discount to the AMGN-based implied valuation, with the current price of $46.95 versus an implied price of $128.57. The gap is driven by INSP’s much lower P/S and EV/Revenue multiples versus AMGN, even though INSP’s EV/EBITDA is only slightly above AMGN’s.
Supporting Metrics
